According to incomplete statistics from Innovation Radar, last week (July 7 to July 13) in the global pharmaceuticals and healthcare sectorA total of 20 financing events were disclosed, with a total financing amount exceeding 5.7 billion US dollars.

Radiopharmaceuticals Become the Key Word in Last Week's Innovative Drug Financing.Swiss Company Nuclidium Completes $99 Million Series B Financing with Radiotherapeutic and Diagnostic Platform Based on Copper IsotopesThis is the single largest disclosed financing in terms of potential amount from last week. The company’s core pipeline, NuriPro, targets metastatic castration-resistant prostate cancer (mCRPC). Its diagnostic application as a PET imaging agent has completed Phase 1 clinical development, and its therapeutic application is about to enter the early research stage.

At the same time,Actithera Inc. also secured $75.5 million in its Series A financing round.Developing small-molecule radioligands, with a focus on the field of cancer treatment. The funding will support the clinical development of fibroblast activation protein (FAP)-targeted radioligand candidates across multiple indications.

A total of 2 companies in the CGT field received financing. Among them,CoRegen, Inc. Secures Over $93 Million. The company targets regulatory T (Treg) cells bySRC-3Genes enable the immune system to recognize and eliminate solid tumors. The funding will support phase 1/2 clinical trials for related projects.NUCLIDIUM Secures Nearly 100 Million Yuan in A+++ Round Financing, The funds will be used to advance the clinical translation of natural killer cell (NK) therapy drugs.

In the field of small molecule drugs,Renasant Bio Completes $54.5 Million Seed Financing Backed by Qiming Venture Partners and OrbiMedThe company is advancing a series of oral pipelines for the treatment of autosomal dominant polycystic kidney disease (ADPKD), aiming to restore the function of key proteins and halt disease progression.

In addition, several companies such as Centivax, Cosminder, and SureTest Bio have received financing.

Readers, please star ⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with friends circle. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"InnoDigest"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommended

Click "InSee", Sharing the Latest Health Trends from Chuangjian Hui